Since the original description by Charles Huggins in 1942 of the heavy dependence of PCa on androgens and the benefits of orchiectomy in PCa patients, androgens, and AR have remained the main therapeutic targets in PCa treatment (43–46). This evidence concerns the gene AR and posterior cortical atrophy.